Fresh Tracks Therapeutics Inc FRTX shares are trading lower by 12.8% to $0.83 Monday morning. The stock is falling, potentially amid profit-taking, after the company Friday announced an $8.25 million buyout of its right to receive future sofpironium bromide payments from Botanix.
Fresh Tracks Therapeutics says the company has entered an APA Amendment with Botanix Pharmaceuticals Limited and its subsidiary, Botanix SB.
Under the terms of the APA Amendment, Botanix will pay $8.25 million in cash in lieu of all remaining amounts potentially payable by Botanix to the company, $6.60 million of which is payable to the company and the remaining $1.65 million is payable to the company's former licensor.
According to data from Benzinga Pro, FRTX has a 52-week high of $3.54 and a 52-week low of $0.45.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.